Lot certificates

You’ll see American Peptides on the lab’s copy. They’re our supplier.

• 5 mg, lot SERMO5-0318: 99.80% purity (RP-HPLC), 6.36 mg measured, identity confirmed by mass spec. Issued 2026-04-03 by Bioviridian Inc.. Verify certificate COA3372

Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.

What researchers study it for

• Tests of whether the pituitary can release GH
• Children with unexplained GH deficiency
• How GH pulses are timed

How it is thought to work

It engages GHRH receptors on the front part of the pituitary, and the output it triggers is growth hormone alone. Scientists have also used it as a tool to study the back-and-forth between GHRH and somatostatin, the hormone that holds GH back, and how the two together create pulses of GH.

Where the research stands

Once approved by FDA as Geref. It once sold in the US under the brand Geref, with approvals in 1990 and 1997. EMD Serono stopped making it, the approval was pulled in 2009, and in 2013 FDA stated the withdrawal had nothing to do with safety or effectiveness.

Sources

1. Prakash A, Goa KL (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.. BioDrugs.
2. Food and Drug Administration, HHS (2013). Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095, Docket FDA-2012-P-1071). Federal Register.
3. Achermann JC, Hindmarsh PC, Robinson IC, Matthews DR, et al. (1999). The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.. Clin Endocrinol (Oxf).
4. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne).